To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab in comparison to ezetimibe as add-on therapy to stable maximally tolerated daily statin therapy in high cardiovascular (CV) risk patients with hypercholesterolemia in Asia.